Delivering on our Promise: Aratana Therapeutics Highlights Diversified Portfolio

At Aratana, we are focused on delivering solutions for unmet and underserved medical needs in pets. Our name not only means “new beginning,” it defines our approach to developing therapeutic solutions for conditions that currently have few, if any, treatment options. Over the past few months, we’ve achieved a number of highlights in our diversified portfolio. As we report our third quarter results, here are some of the landmarks Aratana has achieved with our therapeutic candidates:

  • AT-001 (grapiprant, EP4 receptor antagonist for osteoarthritis pain): Aratana completed enrollment in the pivotal field effectiveness study in client-owned dogs at the end of October; Aratana continues to anticipate top-line results by the end of 2014 and marketing approval in 2016.
  • AT-002 (capromorelin, ghrelin agonist for appetite stimulation): Aratana continues to enroll the pivotal field effectiveness trial in client-owned dogs and continues to anticipate top-line results in the first quarter of 2015 and marketing approval in 2016.
  • AT-003 (bupivacaine extended release injectable suspension for post-operative pain): During the quarter, Aratana announced positive results of a pilot study in client-owned dogs and met with the FDA to discuss the design of the pivotal field effectiveness which it expects to start by the end of 2014. Aratana continues to anticipate top-line results in the second quarter of 2015 and marketing approval in 2016.
  • In October 2014, investigators presented initial clinical trial results at the Veterinary Cancer Society meeting on AT-004, our partnered product in the U.S. and Canada to aid in the treatment of B-cell lymphoma.
  • Aratana continues to enroll dogs in two studies investigating the use of AT-005, the Company’s conditionally licensed monoclonal antibody to aid in the treatment of T-cell lymphoma, in combination with chemotherapy. Aratana commenced a limited commercial introduction of AT-005 in the fourth quarter of 2014. After receipt of a full license for AT-005 from the United States Department of Agriculture (USDA), which Aratana continues to anticipate in 2015, the Company plans to further expand commercial availability.
  • During the third quarter of 2014, the Company received positive results from the recently closed study of AT-006, the Company’s partnered antiviral for treatment of ocular lesions associated with feline ocular herpes infection.  The Company anticipates that the study results will assist in designing a plan for concurrent U.S. and EU product development.

Recent News Posts

View All